What are the current treatment guidelines for a patient with seronegative rheumatoid arthritis following chickenpox, presenting with polyarthralgia and burning sensations in the soles and palms for over a year, who is already on triple disease‑modifying antirheumatic drugs (methotrexate, sulfasalazine, hydroxychloroquine)?

Treatment Approach for Seronegative RA Post-Chikungunya with Persistent Symptoms Despite Triple DMARD Therapy

For a patient with seronegative rheumatoid arthritis following chikungunya infection who remains symptomatic on triple conventional synthetic DMARDs (methotrexate, sulfasalazine, hydroxychloroquine) for over one year with polyarthralgia and burning sensations in palms and soles, you should escalate to a biologic DMARD or targeted synthetic DMARD (JAK inhibitor), specifically switching to a different mechanism of action rather than adding another conventional synthetic DMARD 1, 2.

Critical Diagnostic Consideration

Before escalating therapy, you must distinguish between:

• True inflammatory disease activity (persistent synovitis requiring treatment escalation)
• Post-chikungunya chronic pain syndrome (non-inflammatory pain that won't respond to immunosuppression)
• Peripheral neuropathy (the burning sensation in palms/soles suggests small fiber neuropathy, which may be post-viral rather than RA-related)

The burning sensation in palms and soles is not typical of RA synovitis and strongly suggests either post-chikungunya neuropathic pain or small fiber neuropathy, which will not improve with additional DMARDs.

Treatment Escalation Algorithm

Step 1: Confirm Active Inflammatory Disease

Assess disease activity using validated measures 1:

• DAS28 score: Moderate activity (>3.2 to ≤5.1) or high activity (>5.1)
• CDAI: Moderate (>10 to ≤22) or high (>22)
• Check inflammatory markers (CRP, ESR)
• Document objective synovitis (swollen joint count)

If no objective synovitis is present, escalating immunosuppression is inappropriate. The symptoms may represent post-chikungunya chronic arthralgia or neuropathy requiring different management (neuropathic pain medications, physical therapy).

Step 2: If Active Disease Confirmed - Add Biologic or Targeted Synthetic DMARD

The 2026 PANLAR guidelines strongly recommend adding a biologic DMARD or targeted synthetic DMARD over continuing to add conventional synthetic DMARDs when triple therapy fails 1. The 2021 ACR guidelines similarly conditionally recommend adding a biologic/targeted synthetic DMARD over triple therapy for patients on maximally tolerated methotrexate who are not at target 2.

Preferred Options (in order):

1. TNF inhibitors (adalimumab, etanercept, infliximab, golimumab, certolizumab)

   • Most established evidence base
   • Continue methotrexate as combination therapy improves outcomes 1

2. IL-6 inhibitors (tocilizumab, sarilumab)

   • Can be used as monotherapy if methotrexate must be discontinued 1
   • Strong evidence for efficacy

3. JAK inhibitors (tofacitinib, baricitinib, upadacitinib)

   • CAUTION: If patient is ≥65 years, has cardiovascular risk factors, history of smoking, or malignancy risk, JAK inhibitors should be used with extreme caution due to increased risk of major adverse cardiovascular events and cancer demonstrated in the ORAL Surveillance study 1
   • Can be used as monotherapy if needed 1

4. Other biologics: Abatacept (co-stimulation inhibitor) or rituximab (B-cell depleting)

Step 3: Switching Strategy

When switching from failed triple conventional synthetic DMARDs, swapping to a different mechanism of action (biologic or targeted synthetic DMARD) is strongly recommended over cycling to another conventional synthetic DMARD 1, 2.

Management of Neuropathic Symptoms

The burning sensation in palms and soles requires separate evaluation and treatment:

• Consider: Post-chikungunya neuropathy, small fiber neuropathy, or DMARD-related neuropathy (methotrexate can rarely cause peripheral neuropathy)
• Workup: Nerve conduction studies, consider skin biopsy for small fiber neuropathy
• Treatment: Neuropathic pain medications (gabapentin, pregabalin, duloxetine) - these symptoms will NOT improve with additional immunosuppression

Treat-to-Target Approach

A treat-to-target strategy is strongly recommended 2:

• Reassess disease activity every 3-6 months 1
• Target: Low disease activity (DAS28 ≤3.2) or remission (DAS28 ≤2.6) 1
• If target not achieved after 3-6 months on new biologic, consider switching to another biologic with different mechanism of action 1

Critical Pitfalls to Avoid

1. Don't add more conventional synthetic DMARDs - The patient has already failed triple therapy; further conventional synthetic DMARD combinations are not recommended 1, 2

2. Don't treat neuropathic pain with immunosuppression - Burning sensations in palms/soles suggest neuropathy, not synovitis

3. Don't ignore post-chikungunya chronic pain syndrome - Chikungunya can cause persistent arthralgia lasting years without active inflammation; this requires pain management, not escalating immunosuppression

4. Don't use JAK inhibitors as first-line biologic in high-risk patients - Assess cardiovascular risk, age, smoking history, and malignancy risk before selecting JAK inhibitors 1

5. Don't discontinue methotrexate when adding biologics - Combination therapy with conventional synthetic DMARDs (especially methotrexate) improves biologic efficacy and survival rates 1

Glucocorticoid Management

If the patient is on glucocorticoids to maintain control, prioritize adding/switching DMARDs over continuing glucocorticoids 2. Glucocorticoids should be tapered to the lowest effective dose for the shortest duration 1.